Skip to main content
TipRanks
Go Ultimate75% OFF

Novanta (NOVT) AI Stock Analysis

296 Followers
NOVT

Novanta

(NASDAQ:NOVT)

Select Model
Rating:62Neutral
Price Target:$131.00â–²(14.51% Upside)
Action:reiterated
Date:11/11/26

NOVT scores as moderately attractive overall: the biggest positives are improving cash generation and strong, upbeat guidance with expected EBITDA/cash-flow growth. Offsetting these are compressed profitability and higher debt, plus weak technical trends and a very high P/E valuation that increases execution risk.

Positive Factors
Growth outlookStrong reported and organic growth guidance, alongside expected EBITDA expansion, indicates durable demand across Novanta’s medical and automation platforms. Continued growth would support operating leverage, increase reinvestment capacity, and strengthen the company’s position in mission-critical OEM systems.
Negative Factors
Higher leverageThe Riverpoint acquisition materially increased debt and financing obligations, reducing balance-sheet flexibility compared with the pre-acquisition profile. Higher leverage can constrain future capital allocation, increase sensitivity to operating setbacks, and make margin recovery more important for maintaining financial resilience.

Novanta Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across regions, revealing where Novanta earns its sales and how exposed the company is to local demand cycles, regulatory differences, or currency swings. Helps gauge growth opportunities in different markets and identify concentration risk if a large share comes from one region.

$0.00$25.00M$50.00M$75.00M$100.00M$125.00MMar 21Apr 21Jul 21Oct 21Dec 21Apr 22Jul 22Sep 22Dec 22Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Apr 26Jul 26
Chart Insights

Novanta's top-line is being driven by the U.S., which accounts for the bulk of revenue and has shown consistent acceleration; non-U.S. markets—notably China and Rest of Europe—have rebounded recently, helping offset weakness in Germany and small 'Other' markets. Management's booking growth and surging design wins validate the geographic recovery and support mid-single-digit organic guidance, but call details flag an underlying organic revenue contraction and Precision Medicine softness that could blunt near-term upside if bookings don't convert.

Data provided by:The Fly

Novanta (NOVT) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%NOVT+15.30%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.33B
Dividend Yield
―
Average Volume (3M)
434.63K
Price to Earnings (P/E)
86.3
Beta (1Y)
1.73
Revenue Growth
13.18%
EPS Growth
-9.22%
Country
US
Employees
3,000
Sector
Technology
Sector Strength
61
Industry
Hardware, Equipment & Parts

Novanta Business Overview & Revenue Model

Company Description

Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplie...

How the Company Makes Money

Novanta makes money primarily by selling engineered components, modules, and subsystems to OEM customers, generating revenue largely from product sales recognized when control transfers under customer contracts. Key revenue streams generally align to...

Novanta Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-21.63%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Novanta reported broad-based revenue, organic growth, bookings, backlog, adjusted EBITDA, adjusted EPS, and cash-flow gains; completed and integrated its largest acquisition; and highlighted substantial product, design-win, and end-market momentum. The principal challenges were temporary Stockport production and shipment issues, lower near-term gross margins, a decline in precision medicine revenue, manufacturing-transition costs, tight component supply, and higher leverage after the acquisition. Management characterized the major operational issues as temporary and maintained strong 2026 and 2027 growth expectations.

Positive Updates

Strong Third-Quarter Revenue and Organic Growth
Revenue grew 23% on a reported basis to $305 million, including organic growth of nearly 10%, which Novanta described as its strongest organic growth in more than three years.

Negative Updates

Lower Full-Year Gross Margin Outlook
Full-year 2026 adjusted gross margin guidance was reduced to approximately 46.5%, reflecting the temporary headwind from lost factory absorption at Stockport.

Company Guidance

For the fourth quarter of 2026, Novanta expects GAAP revenue to be approximately $306 million-$312 million, reported growth of 18% to 21%, organic revenue growth of 5% to 7%, and approximately $35 million of revenue from Riverpoint Medical; adjusted EBITDA is expected to be between $76 million and $79 million, representing growth of 25%-30% year over year and approximately 25% EBITDA margin, approximately 150 basis points higher than the prior year, while adjusted diluted earnings per share is expected to be in the range of $0.91-$0.96. For full-year 2026, it expects GAAP revenue of approximately $1,135 million -$1,140 million, reported growth of approximately 16%, organic growth of approximately 7%, adjusted gross margins of approximately 46.5%, non-GAAP operating expenses of approximately 27% of sales, depreciation expense of approximately $19 million, stock compensation expense of approximately $38 million, interest expense of approximately $23 million, a non-GAAP tax rate of approximately 21%, diluted weighted average shares outstanding of approximately 42 million, adjusted EBITDA between $274 million and $277 million, year-over-year growth of 24%-25%, adjusted diluted earnings per share in the range of $3.66 to $3.71, year-over-year growth of 11%-13%, operating cash flow of approximately $200 million, year-end gross debt of approximately $818 million, gross leverage ratio of 2.6x, and net leverage of approximately 2.1. Medical Solutions is expected to deliver 2% to 4% organic growth, Automation Enabling Technologies had an outlook of 12% to14% growth, precision medicine is expected to return to growth in late 2027, production in Stockport is expected to resume in the first quarter, and Novanta currently expects a 2027 outlook of more than 15% reported growth and more than 20% adjusted EBITDA growth, with gross margins expected to expand at least 100 basis points next year and a long-term algorithm of mid to high single-digit organic growth.

Novanta Financial Statement Overview

Summary

Financials are solid but not standout: steady TTM revenue growth (~$1.09B) and strong free cash flow (~$140M) support the profile, but profitability has compressed (TTM net margin ~4.9% vs higher levels in 2022–2024) and total debt stepped up meaningfully in the latest TTM period, increasing balance-sheet risk if margins don’t recover.

Income Statement

64Positive

Balance Sheet

67Positive

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.09B980.60M949.25M881.66M860.90M706.79M
Gross Profit469.50M407.81M421.55M399.90M378.47M300.33M
EBITDA158.84M153.05M179.86M169.92M160.62M125.47M
Net Income53.13M53.83M64.09M72.88M74.05M50.33M
Balance Sheet
Total Assets3.17B1.81B1.39B1.23B1.24B1.23B
Cash, Cash Equivalents and Short-Term Investments149.22M380.87M113.99M105.05M100.11M117.39M
Total Debt893.25M341.61M471.00M404.56M489.38M493.40M
Total Liabilities1.55B492.82M642.81M552.60M663.63M706.59M
Stockholders Equity1.62B1.31B745.70M673.46M577.59M521.29M
Cash Flow
Free Cash Flow140.44M48.43M141.35M100.11M71.14M72.45M
Operating Cash Flow164.69M64.06M158.51M120.08M90.78M94.63M
Investing Cash Flow-1.22B-74.32M-208.19M-19.89M-42.54M-306.70M
Financing Cash Flow1.12B276.33M56.94M-97.85M-60.15M204.75M

Novanta Technical Analysis

Technical Analysis SentimentNegative
Last Price114.40

Price Trends

50DMA139.61Negative
100DMA145.41Negative
200DMA142.02Negative

Market Momentum

MACD-6.01Positive
RSI33.73Neutral
STOCH8.60Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Negative. The current price of 114.40 is below the 20-day moving average (MA) of 137.18, below the 50-day MA of 139.61, and below the 200-day MA of 142.02, indicating a bearish trend. The MACD of -6.01 indicates Positive momentum. The RSI at 33.73 is Neutral, neither overbought nor oversold. The STOCH value of 8.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NOVT.

Novanta Risk Analysis

Novanta disclosed 38 risk factors in its most recent earnings report. Novanta reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our operating results depend in part on our ability to contain or reduce costs. There is substantial price competition in our industry and upward pressure on material and labor costs. Our success and profitability will depend on our ability to maintain a competitive cost and price structure.Q4, 2024
2.The loss of sales, or significant reductions in orders from, any major customers may have a material adverse effect on us.Q4, 2024
3.The effects of climate change and related regulatory responses may adversely impact our business.Q4, 2023

Novanta Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

NOVT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MKSIMKSI77Outperform$13.82B22.9420.40%0.48%24.53%116.17%
TDYTDY77Outperform$28.91B28.609.49%―8.43%26.65%
CGNXCGNX73Outperform$8.12B33.3815.31%0.71%15.82%121.72%
OSISOSIS68Neutral$2.96B19.6518.92%―2.91%6.65%
COHRCOHR63Neutral$40.07B40.039.30%―30.84%582.28%
NOVTNOVT62Neutral$4.33B86.293.62%―13.18%-9.22%
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%

* Technology Sector Average

Performance Comparison

0%50%100%150%200%NOVTCGNXCOHRMKSIOSISTDYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NOVT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NOVTNovanta114.4013.7513.66%
CGNXCognex48.2012.2534.09%
COHRCoherent Corp.203.4360.4942.32%
MKSIMks Inc.204.3861.1242.66%
OSISOSI Systems188.31-49.51-20.82%
TDYTeledyne627.95134.0127.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026